Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ralph Defronzo
University of Texas Hlth Science Center, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
AstraZeneca
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Entity will provide the study drug gratis.
Effect of SGLT2 inhibitors on hepatic glucose metabolism: role of autonomic nervous system
SGLT2 inhibitor is a novel class of drugs approved by the FDA for the treatment of type 2 diabetes (T2DM). In addition to lowering the plasma glucose concentration, members of this class cause increase in hepatic glucose production, increase in fat oxidation and ketone production, all of which have important clinical significance. In the present grant proposal we will study the mechanisms responsible for these metabolic actions of this class of drugs with emphasis on the role of autonomic nervous system.
Filed on September 18, 2017.
Tell us what you know about Ralph Defronzo's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Ralph Defronzo”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Ralph Defronzo | University of Texas Hlth Science Center | Conflict of Interest | AstraZeneca | $100,000 - $149,999 |
| Ralph Defronzo | University of Texas Hlth Science Center | Conflict of Interest | AstraZeneca | $100,000 - $149,999 |
| Ralph Defronzo | University of Texas Hlth Science Center | Conflict of Interest | AstraZeneca | $100,000 - $149,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.